Biologic Targets Mutant HER2 Protein
This is a HER2 news story, published by ScienceDaily, that relates primarily to HER2 news.
HER2 news
For more HER2 news, you can click here:
more HER2 newsHER2 news
For more HER2 news, you can click here:
more HER2 newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
mutant HER2 cancer cells. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest mutant HER2 tumors news, cancer biologics news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
mutant cancer proteinScienceDaily
•Engineering creates molecules that target cancer-causing proteins
77% Informative
A new study describes the development of a biologic, a drug derived from natural biological systems, that targets a mutant cancer protein called HER2 .
Antibodies are large, Y-shaped proteins that bind to specific targets and flag down immune cells to destroy those targets.
The new findings revolve around HER2 , a protein that occurs on the surfaces of many cell types.
The T cell engager molecule was the most potent of the things they tried, but there could be better options they have not tested yet.
They plan to apply their antibody engineering technique to develop highly specific antibodies that may treat other mutant proteins causing cancers.
This work was supported by National Institutes of Health grant P30CA01608.
VR Score
86
Informative language
91
Neutral language
52
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links